ILMN

Illumina ($ILMN) CEO and SVP Purchase $1.5M in Shares Amid Stock Plunge, Following U.S.-China Medical Device Tariff Reduction Agreement

05/14/2025 20:35

Illumina ($ILMN) CEO Jacob Thaysen and SVP Ankur Dhingra have purchased a combined $1.5 million worth of company stock, signaling insider confidence as the biotechnology firm's shares have plunged over 40% in 2025. CEO Jacob Thaysen made two consecutive purchases on May 12 and May 13. In the first transaction, he acquired 6,500 shares at an average price of $81.20, totaling $527,832.50. The following day, he purchased an additional 5,850 shares at an average price of $81.51 for a total of $476,814. Alongside these transactions, SVP Ankur Dhingra bought 6,100 shares at an average price of $81.21, amounting to $495,381 on May 12. Thaysen's consecutive purchases represent a strong insider trading signal, suggesting executive confidence in the current stock price level. These acquisitions come after the company's shares have dramatically declined from the $140s earlier this year to the $70-80 range recently. Illumina recently reported its first quarter earnings on May 9, posting an earnings per share (EPS) of $0.97, exceeding analyst expectations of $0.94. This marks a substantial improvement from $0.09 in the same period last year. However, revenue declined 3.3% year-over-year to $1.04 billion, though slightly above the anticipated $1.03 billion. Thaysen's stock purchases occurred immediately following an agreement between the United States and China to significantly reduce reciprocal tariffs on medical devices. Announced on May 12, the agreement reduces U.S. tariffs on Chinese medical goods from 145% to 30%, while China cuts tariffs on U.S. products from 125% to 10%. This 90-day tariff reduction is a significant positive development for medical device and pharmaceutical companies like Illumina that source raw materials and components from China. In March, Illumina announced a $100 million cost reduction program to mitigate potential revenue declines, particularly from its Greater China business affected by import restrictions. The company has revised its 2025 outlook, now expecting core revenue to decline between 1% and 3%, with revenue from Greater China projected between $165 million and $185 million. On March 25, Illumina announced that activist investor Keith Meister would join its board, with Scott Gottlieb appointed as chairman. Meister, who leads Corvex Management, holds a 1.07% stake in Illumina and is advocating for value-creating strategies. These board changes are expected to significantly influence the company's management direction. Illumina also announced a partnership with Tempus on April 15 to drive genomic AI innovation, part of its strategy to lead the future of precision medicine. Additionally, in January, the company revealed plans to build a massive genetic database through a $320 million investment with Truveta. However, the company still faces challenges. On February 21, Bernstein analysts identified Roche's new gene sequencing device as superior to Illumina's for decoding diseases, raising concerns about Illumina's market position and negatively impacting the stock. Leerink Partners also noted on February 10 that $4 billion in NIH cost cuts would adversely affect large academic institutions and research centers, potentially impacting sales for life sciences technology firms like Illumina due to cautious spending by researchers. Examining Illumina's financial position, the company generated $240 million in cash from operations in Q1, with free cash flow at $208 million. It maintains a strong liquidity position with total cash of $1.24 billion. However, its debt-to-equity ratio stands at 110.09%, indicating a relatively high level of debt. Despite the recent insider purchases and U.S.-China tariff reduction agreement, Illumina's stock remains volatile and has experienced substantial decline since early this year. Nevertheless, the insider buying activity demonstrating executive confidence and better-than-expected earnings results could provide positive signals to investors. While the temporary easing of U.S.-China trade tensions and cost-cutting initiatives are expected to benefit the company in the short term, competitive pressures and reduced research spending continue to pose challenges.

You can receive notifications when news is published.